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Hypercholesterolemia is a major cause of cardiovascular disease and can be treated by targeting bile acid
and cholesterol metabolism. Vergnes et al. (2013) now identify Diet1 as a novel regulator of fibroblast growth
factor 15/19 production and bile acid biosynthesis.The metabolism of bile acids and choles-
terol is tightly interrelated. Bile acids are
synthesized from cholesterol in liver,
secreted from hepatocytes into bile,
and stored in the gall bladder. During a
meal, bile empties into the small intes-
tine, where bile acids facilitate the solu-
bilization and absorption of fat and fat-
soluble nutrients. Most of the bile acids
are reabsorbed from the small intestine
by active transport in the terminal ileum
and returned via the portal circulation to
the liver for resecretion into bile. This
process, termed the enterohepatic circu-
lation, is repeated multiple times during a
meal and serves to efficiently recycle bile
acids between the hepatobiliary and
intestinal compartments. Bile acids that
escape intestinal absorption are ex-
creted in the feces, and this route ac-
counts for almost half the cholesterol
eliminated from the body each day.
Hastening the loss of cholesterol as bile
acids is the basis for the therapeutic
approach of using bile acid seques-
trants, which block intestinal bile acid
absorption, to reduce plasma cholesterol
levels.
Bile acid synthesis is subject to nega-
tive feedback regulation, which requires
the bile acid-activated farnesoid X recep-
tor (FXR) and the atypical nuclear recep-
tor, small heterodimer partner (SHP).
More recently, an important role for gut-
liver signaling via the endocrine polypep-
tide hormone fibroblast growth factor
(FGF) 15 (human ortholog FGF19) was
revealed (Inagaki et al., 2005; Lunda˚sen
et al., 2006). In this pathway, bile acids
activate FXR in ileal enterocytes to induce
production of FGF15/19 (Figure 1). After
its release into the circulation, FGF15/19
acts on hepatocytes through its cell sur-
face receptor, a complex of the b-klotho816 Cell Metabolism 17, June 4, 2013 ª2013protein and FGF receptor 4 (FGFR4),
and signals to repress bile acid synthesis.
This complex molecular sensor links syn-
thesis of bile acids to changes in their
intestinal flux.
Over a dozen years ago, a locus on
mouse proximal chromosome 2 (human
chromosome 10p12) was identified in
a substrain of C57BL/6 mice (C57BL/
6ByJ). The apparent spontaneous muta-
tion conferred resistance to diet-induced
hypercholesterolemia and atheroscle-
rosis and was associated with increased
bile acid synthesis and elevated serum
bile acid levels (Phan et al., 2002). In a
true tour de force, Vergnes et al., (2013)
used high-resolution genetic mapping to
identify the gene responsible for this
phenotype—termed Diet1—and pro-
ceeded to partially unravel its function.
They identify Diet1 as a critical regulator
of bile acid synthesis and, thereby,
cholesterol homeostasis.
Aside from the role of FXR, the factors
that control synthesis and secretion of
FGF15/19 are poorly understood. In this
context comes the unexpected dis-
covery of a previously uncharacterized
gene by Vergnes et al. (2013). Back-
crossing C57BL/6ByJ and CAST/EiJ
mice and following genetic markers and
serum bile acid levels in an extensive
number of recombinants and progeny,
Vergnes et al. (2013) were able to narrow
the location of the locus from a 20 cM
region to a single large gene (Diet1) and
ultimately identify the Diet1 mutation in
C57BL/6ByJ mice. Initial characterization
revealed that the Diet1 gene is ex-
pressed primarily in the intestinal epithe-
lium and encodes a 236 kDa protein with
sequence similarity to endotubin, an
endosomal integral membrane protein
important for junction integrity in intesti-Elsevier Inc.nal epithelial cells. Mice lacking Diet1
exhibit all the hallmarks of an impaired
ability to repress hepatic bile acid syn-
thesis, including bile acid overproduc-
tion, an increased whole-body bile acid
pool, increased plasma bile acid levels,
increased fecal bile acid excretion, and
reduced plasma cholesterol levels. As
Diet1 is not expressed in liver, the search
for a mechanism focused on the intes-
tine, where ileal FGF15/19 messenger
RNA (mRNA) and protein expression
were reduced in the absence of Diet1.
Transgenic expression of Diet1 in intes-
tine restored FGF15/19 expression and
repression of hepatic bile acid synthesis
in C57BL/6ByJ mice. The repression of
hepatic bile acid synthesis could also
be restored by adenoviral-mediated de-
livery of FGF15/19 to the liver, suggest-
ing that impaired FGF15/19 production
largely drives the altered bile acid and
cholesterol homeostasis associated with
loss of Diet1. Mechanistically, expression
of Diet1 increased ileal FGF15/19 mRNA
expression as well as the translation and/
or secretion of FGF15/19 protein. A
possible direct role of Diet1 in the vesic-
ular storage and secretion of FGF15/19
protein is supported by the finding of
their colocalization in cytosolic vesicles
and their coimmunoprecipitation as an
apparent complex. This would be similar
to the proposed role of the related pro-
tein endotubin in the trafficking of pro-
teins and tight junction components
(McCarter et al., 2010).
This study establishes Diet1 as an
important new regulator of the FGF15/
19 pathway and the whole-body levels
of bile acids and cholesterol (Figure 1).
The findings also reiterate the impor-
tance of the FGF15/19 pathway in regu-
lating bile acid and lipid metabolism in
Figure 1. Role of Diet1 in FGF15/19 Signaling and Bile Acid Homeostasis
Schematic showing the major route for hepatic synthesis and the transporters involved in the enterohepatic circulation of bile acids (black diamonds). Ileal bile
acids activate the nuclear receptor FXR, which stimulates expression of the enterokine, FGF15/19. Diet1 facilitates FGF15/19 production. After its secretion,
FGF15/19 travels to the liver, where it signals through its cell surface receptor, a complex of fibroblast growth factor receptor 4 (FGFR4) and the b-klotho protein,
to repress expression of cholesterol 7a-hydroxylase (CYP7A1) and decrease bile acid synthesis. Loss of Diet1 results in reduced FGF15/19 synthesis and secre-
tion, leading to increasedCYP7A1 expression and hepatic utilization of cholesterol for bile acid synthesis, which reduces plasma cholesterol levels. ASBT, apical
sodium-dependent bile acid transporter; BSEP, bile salt export pump; NTCP, Na+-taurocholate cotransporting polypeptide; OSTa/b, organic solute transporter
alpha-beta).
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tions remain regarding the full range of
physiological actions of FGF15/19. It is
also unknown whether genetic variation
at this locus regulates bile acid and lipid
homeostasis in humans and other spe-
cies, but there are tantalizing clues. A
phenotype remarkably similar to that of
C57BL/6ByJ mice was reported for a
Houston, TX colony of hypercholester-
olemia-resistant New Zealand white
rabbits with increased cholesterol catab-
olism to bile acids secondary to impaired
feedback inhibition (Poorman et al.,
1993). In humans, at one extreme is the
case of the 88-year-old man with an
elevated daily bile acid synthesis,
increased bile acid pool, and normal
plasma cholesterol levels, despite con-
suming 20–30 eggs each day for
more than 15 years (Kern, 1991). More
common is bile acid overproduction-associated hypertriglyceridemia (Ga¨lman
et al., 2011) and conditions where low
FGF19 levels may be driving excess
bile acid synthesis, such as in cases
of diarrhea-predominant irritable bowel
syndrome and idiopathic bile acid
malabsorption (Walters et al., 2009).
Since intestinal bile acid absorption is
thought to be normal in most of those in-
dividuals, impaired function of Diet1 or
dysregulation of Diet1-related mecha-
nisms may underlie the uncoupling of
the normal crosstalk between intestinal
bile acid flux and hepatic bile acid
synthesis.
In summary, Vergnes et al., (2013)
clearly demonstrate that altered bile acid
homeostasis secondary to loss of Diet1
and impaired FGF15/19 production un-
derlies the resistance to hypercholester-
olemia in C57BL/6ByJ mice. These
findings have important biological andCell Metabolismtherapeutic implications beyond hyper-
cholesterolemia. The link between bile
acids and metabolic regulation is well es-
tablished but incompletely understood in
a variety of clinical conditions, including
hypertriglyceridemia, obesity, hepatic
steatosis, the control of glucose meta-
bolism, and response to bariatric surgery.
The identification of this novel regulator of
bile acid homeostasis adds to a steady
diet of important recent discoveries that
have transformed this field.REFERENCES
Ga¨lman, C., Angelin, B., and Rudling, M. (2011).
J. Intern. Med. 270, 580–588.
Inagaki, T., Choi, M., Moschetta, A., Peng, L.,
Cummins, C.L., McDonald, J.G., Luo, G., Jones,
S.A., Goodwin, B., Richardson, J.A., et al. (2005).
Cell Metab. 2, 217–225.
Kern, F., Jr. (1991). N. Engl. J. Med. 324, 896–899.17, June 4, 2013 ª2013 Elsevier Inc. 817
Cell Metabolism
PreviewsLunda˚sen, T., Ga¨lman, C., Angelin, B., and
Rudling, M. (2006). J. Intern. Med. 260, 530–536.McCarter, S.D., Johnson, D.L., Kitt, K.N.,
Donohue, C., Adams, A., and Wilson, J.M. (2010).
Traffic 11, 856–866.818 Cell Metabolism 17, June 4, 2013 ª2013Phan, J., Pesaran, T., Davis, R.C., and Reue, K.
(2002). J. Biol. Chem. 277, 469–477.Poorman, J.A., Buck, R.A., Smith, S.A., Overturf,
M.L., and Loose-Mitchell, D.S. (1993). J. Lipid
Res. 34, 1675–1685.Elsevier Inc.Vergnes, L., Lee, J.M., Chin, R.G., Auwerx, J., and
Reue, K. (2013). Cell Metab. 17, this issue,
916–928.
Walters, J.R., Tasleem, A.M., Omer, O.S., Brydon,
W.G., Dew, T., and le Roux, C.W. (2009). Clin.
Gastroenterol. Hepatol. 7, 1189–1194.
